Kezar Life Sciences, Inc.

NasdaqGS:KZR Stock Report

Market Cap: US$60.0m

Kezar Life Sciences Dividend

Dividend criteria checks 0/6

Kezar Life Sciences does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.9%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$1.40
Dividend yield forecast in 3Yn/a

Recent dividend updates

No updates

Recent updates

Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?

Dec 08
Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?

FDA clears Kezar Life Sciences' drug application for autoimmune hepatitis treatment

Oct 03

Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?

Aug 15
Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?

Kezar Life Sciences GAAP EPS of -$0.25 beats by $0.02

Aug 11

Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case

Jul 27

Kezar Life Sciences appoints Nick Mordwinkin as chief business officer

Jul 11

We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Jan 03
We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation

We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Apr 05
We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like

Mar 01
Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like

Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings

Jan 25
Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings

Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans

Dec 21
Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans

Kezar Life Sciences selected for the Nasdaq Biotechnology Index

Dec 14

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if KZR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KZR's dividend payments have been increasing.


Dividend Yield vs Market

Kezar Life Sciences Dividend Yield vs Market
How does KZR dividend yield compare to the market?
SegmentDividend Yield
Company (KZR)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.8%
Industry Average (Biotechs)2.9%
Analyst forecast in 3 Years (KZR)n/a

Notable Dividend: Unable to evaluate KZR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KZR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate KZR's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as KZR has not reported any payouts.


Discover strong dividend paying companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.